Menu
Search
|

Menu

Close
X

MYOS RENS Technology Inc MYOS.OQ (NASDAQ Stock Exchange Capital Market)

1.45 USD
-- (--)
As of Jun 21
chart
Previous Close 1.45
Open --
Volume --
3m Avg Volume 10,994
Today’s High --
Today’s Low --
52 Week High 2.37
52 Week Low 1.05
Shares Outstanding (mil) 5.84
Market Capitalization (mil) 7.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
0
FY15
0
EPS (USD)
FY18
-0.186
FY17
-0.094
FY16
-0.921
FY15
-1.642
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
40.93
Price to Sales (TTM)
vs sector
28.69
5.98
Price to Book (MRQ)
vs sector
1.55
37.58
Price to Cash Flow (TTM)
vs sector
--
36.00
Total Debt to Equity (MRQ)
vs sector
0.00
18.42
LT Debt to Equity (MRQ)
vs sector
0.00
7.52
Return on Investment (TTM)
vs sector
-67.54
62.11
Return on Equity (TTM)
vs sector
-68.27
73.68

EXECUTIVE LEADERSHIP

Robert Hariri
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Joseph Mannello
Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Victor Mandel
Director, Since 2016
Salary: --
Bonus: --
Christopher Pechock
Director, Since 2014
Salary: --
Bonus: --
Bin Zhou
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Consumer Non-Cyclicals
Industry: Food Processing
Address:

45 Horsehill Rd Ste 106
CEDAR KNOLLS   NJ   07927-2009

Phone: +1973.5090444

MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.

SPONSORED STORIES